AG

Arjun Goyal

Managing Director at Vida Ventures, LLC

Boston, Massachusetts

Overview 

Arjun Goyal is the Co-Founder and Managing Director at Vida Ventures in Boston, Massachusetts, with a strong background in medical education, clinical research, and venture capital. He has successfully invested in and served on the boards of various biotech and pharmaceutical companies, including Alterome Therapeutics, Quanta Therapeutics, and Centessa Pharmaceuticals, contributing to their growth and success.

Work Experience 

  • Co-Founder and Managing Director

    2017 - Current

    Vida Ventures is a life sciences investment firm founded in 2017 and manages ~$2B AUM. We are passionate about building and funding breakthroughs in biomedicine. Our mission is to bring science to life and advance transformative biomedical innovations that have the potential to make a meaningful impact for patients.

Vida Ventures is a next-generation life sciences investment firm .

  • Venture Capital Advisor

    2022

    Venture Capital Advisors (VCAs) are general partners from VC firms providing HBS/ Harvard students & faculty with fundraising information, and feedback on their idea, business models, and other core aspects of their new ventures.

  • Member Board Of Directors

    2021

    Alterome Therapeutics is developing alteration-specific therapeutics for high value oncology targets

Alterome Therapeutics is a biopharmaceutical company developing alteration-specific targeted therapies.

Raised $231,000,000.00 from Driehaus Capital Management, Goldman Sachs, Boxer Capital, Colt Ventures, Digitalis Ventures, Invus, Vida Ventures, Blue Owl, Nextech Invest and Canaan Partners.

  • Co-Founder and Board Member

    2021

    Affini-T Therapeutics is developing cell therapies focused on oncogenic drivers for solid tumors

Affini-T Therapeutics is a biotechnology company developing T-cell therapies for patients suffering from cancer.

Raised $175,000,000.00 from Parker Institute for Cancer Immunotherapy, Fred Hutchinson, Agent Capital, Alexandria Venture Investments, Humboldt Fund, Vida Ventures, Erasca Ventures, Leaps by Bayer and Catalio Capital Management.

  • Member Board Of Directors

    2021

    Centessa Pharmaceuticals is developing medicines focused on rare diseases and immuno-oncology NASDAQ: CNTA Compensation Committee Nom/Gov Committee Audit Committee

Centessa Pharmaceuticals is a next-generation biopharmaceutical company that aims to reshape the traditional drug development process.

Raised $875,000,000.00 from Oberland Capital.

  • Member Board Of Directors

    2020

    Quanta Therapeutics is developing small molecules to oncogenic drivers Compensation Committee Nom/ Gov Committee

Quanta is a biotechnology company uncovering novel cancer therapeutic candidates using allosteric modulation to target driver oncogenes.

Raised $140,699,993.00 from Longitude Capital, WS Investment Company, Avidity Partners, GC&H Investments, Sofinnova Investments, Biotechnology Value Fund, Vida Ventures, AbbVie and Surveyor Capital.

  • Member Board Of Directors

    2020

    Scorpion Therapeutics is developing medicines for oncology Compensation Committee, Chair Nom/ Gov Committee

Scorpion Therapeutics is a clinical-stage oncology company that specializes in precision medicine for cancer patients.

Raised $420,000,000.00 from Lightspeed Venture Partners, Invus, EcoR1 Capital, Boxer Capital, Surveyor Capital, Fidelity, Logos Capital, Atlas Venture, Casdin Capital and Nextech Invest.

  • Member Board Of Directors

    2017

    Pionyr Immunotherapeutics is developing medicines focused on modulating the tumor microenvironment Gilead acquired Pionyr for ~$1.5B total consideration

Pionyr Immunotherapeutics is a developer of cancer immunotherapies designed to target the tumor microenvironment.

Raised $351,999,999.00 from Gilead Sciences.

  • Member Board Of Directors

    2019 - 2020

    Kinnate Biopharma is developing therapies for BRAF and FGFR driven cancers NASDAQ: KNTE

Kinnate Biopharma develops precision oncology therapeutics to treat patients with genomically-defined cancers.

Raised $194,500,000.00 from Vida Ventures, Fidelity, RA Capital Management, Foresite Capital, Leerink Partners, Logos Capital, Venrock Healthcare Capital Partners, Nextech Invest, Boxer Capital and OrbiMed.

  • Investor

    2018 - 2020

    Asklepios Bio develops gene therapies for rare diseases Bayer acquired Ask Bio for a total consideration of ~$4B

Asklepios BioPharmaceutical is a biotechnology company developing adeno-associated virus (AAV) gene therapies for genetic disorders.

Raised $241,756,252.00 from Scottish Enterprise, Muscular Dystrophy Association and Muscular Dystrophy Association.

Articles About Arjun

Relevant Websites